( auranofin )
3 mg brown / white capsule with tapered ends
To reduce inflammation in
rheumatoid arthritis and retard disease progression. ( This drug is "oral
For anti-inflammatory activity in
Average dosage is 6 mg daily. The
drug is slowly absorbed and distributed through the body, and weeks to
months may be required before full therapeutic effect is achieved.
The most common side effect is
dose-related diarrhea, which occurs at some time in approximately one third
of treated patients and requires discontinuation in 10% to 20 % of patients.
Skin rash has occurred in 4%, mild kidney problems in 1%, and problems with
the platelets in 0.5% of patients.
Ridaura, useful in rheumatoid
arthritis, is an important drug for some patients. It is not believed to be
effective in osteoarthritis, gout, or minor rheumatic conditions. It may or
may not have an eventual role in psoriatic arthritis, ankylosing spondylitis,
and the arthritis of children. If diarrhea is encountered, the dose should
be reduced. As with intramuscular gold injections, patients should be
monitored periodically for blood complications, skin rash, and protein loss
in the urine. Follow your doctor's advice for the particular tests required
and the frequencies with which they are needed. Ridaura is most useful in
the first year or so of rheumatoid arthritis.